PURPOSE: We tested the hypothesis that recombinant human VEGF-A165b and the serine arginine protein kinase (SRPK) inhibitor, SRPIN340, which controls splicing of the VEGF-A pre-mRNA, prevent neovascularization in a rodent model of retinopathy of prematurity (ROP). METHODS: In the 50/10 oxygen-induced retinopathy (50/10 OIR) model that exposes newborn rats to repeated cycles of 24 hours of 50% oxygen alternating with 24 hours of 10% oxygen, pups received intraocular injections of SRPIN340, vehicle, VEGF165b, anti-VEGF antibody, or saline. Whole mounts of retinas were prepared for isolectin immunohistochemistry, and preretinal or intravitreal neovascularization (PRNV) determined by clock hour analysis. RESULTS: The anti-VEGF antibody (P < 0.04), rhVEGF165b (P < 0.001), and SRPIN340 (P < 0.05) significantly reduced PRNV compared with control eyes. SRPIN340 reduced the expression of proangiogenic VEGF165 without affecting VEGF165b expression. CONCLUSIONS: These results suggest that splicing regulation through selective downregulation of proangiogenic VEGF isoforms (via SRPK1 inhibition) or competitive inhibition of VEGF signaling by rhVEGF165b has the potential to be an effective alternative to potential cyto- and neurotoxic anti-VEGF agents in the treatment of pathological neovascularization in the eye.
PURPOSE: We tested the hypothesis that recombinant human VEGF-A165b and the serine arginine protein kinase (SRPK) inhibitor, SRPIN340, which controls splicing of the VEGF-A pre-mRNA, prevent neovascularization in a rodent model of retinopathy of prematurity (ROP). METHODS: In the 50/10 oxygen-induced retinopathy (50/10 OIR) model that exposes newborn rats to repeated cycles of 24 hours of 50% oxygen alternating with 24 hours of 10% oxygen, pups received intraocular injections of SRPIN340, vehicle, VEGF165b, anti-VEGF antibody, or saline. Whole mounts of retinas were prepared for isolectin immunohistochemistry, and preretinal or intravitreal neovascularization (PRNV) determined by clock hour analysis. RESULTS: The anti-VEGF antibody (P < 0.04), rhVEGF165b (P < 0.001), and SRPIN340 (P < 0.05) significantly reduced PRNV compared with control eyes. SRPIN340 reduced the expression of proangiogenic VEGF165 without affecting VEGF165b expression. CONCLUSIONS: These results suggest that splicing regulation through selective downregulation of proangiogenic VEGF isoforms (via SRPK1 inhibition) or competitive inhibition of VEGF signaling by rhVEGF165b has the potential to be an effective alternative to potential cyto- and neurotoxic anti-VEGF agents in the treatment of pathological neovascularization in the eye.
Entities:
Keywords:
VEGF; angiogenesis; retinopathy of prematurity; splicing
Authors: Jeanette Woolard; Wen-Ying Wang; Heather S Bevan; Yan Qiu; Lucia Morbidelli; Rowan O Pritchard-Jones; Tai-Gen Cui; Marto Sugiono; Elizabeth Waine; Rachel Perrin; Rebecca Foster; Jonathon Digby-Bell; Jacqueline D Shields; Cheryl E Whittles; Rosey E Mushens; David A Gillatt; Marina Ziche; Steven J Harper; David O Bates Journal: Cancer Res Date: 2004-11-01 Impact factor: 12.701
Authors: H Ozaki; A Y Yu; N Della; K Ozaki; J D Luna; H Yamada; S F Hackett; N Okamoto; D J Zack; G L Semenza; P A Campochiaro Journal: Invest Ophthalmol Vis Sci Date: 1999-01 Impact factor: 4.799
Authors: Yan Qiu; Heather Bevan; Sudath Weeraperuma; Daniel Wratting; David Murphy; Christopher R Neal; David O Bates; Steven J Harper Journal: FASEB J Date: 2007-11-21 Impact factor: 5.191
Authors: Brandon E Aubol; Kendra L Hailey; Laurent Fattet; Patricia A Jennings; Joseph A Adams Journal: J Mol Biol Date: 2017-05-31 Impact factor: 5.469
Authors: Naseeb K Malhi; Claire L Allen; Elizabeth Stewart; Katherine L Horton; Federica Riu; Jennifer Batson; Winfried Amoaku; Jonathan C Morris; Kenton P Arkill; David O Bates Journal: Am J Physiol Heart Circ Physiol Date: 2022-03-18 Impact factor: 5.125
Authors: R P Hulse; N Beazley-Long; J Hua; H Kennedy; J Prager; H Bevan; Y Qiu; E S Fernandes; M V Gammons; K Ballmer-Hofer; A C Gittenberger de Groot; A J Churchill; S J Harper; S D Brain; D O Bates; L F Donaldson Journal: Neurobiol Dis Date: 2014-08-21 Impact factor: 5.996
Authors: Irene T Ma; Suzanne McConaghy; Kopperuncholan Namachivayam; Brian A Halloran; Ashish R Kurundkar; Krishnan MohanKumar; Akhil Maheshwari; Robin K Ohls Journal: Pediatr Res Date: 2015-01-14 Impact factor: 3.756
Authors: Nikita Ved; Richard P Hulse; Samuel M Bestall; Lucy F Donaldson; James W Bainbridge; David O Bates Journal: Clin Sci (Lond) Date: 2017-03-24 Impact factor: 6.124